<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97358">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767857</url>
  </required_header>
  <id_info>
    <org_study_id>2012-PT023</org_study_id>
    <nct_id>NCT01767857</nct_id>
  </id_info>
  <brief_title>A Study Using MABp1 To Increase Overall Survival In Patients With Colorectal Cancer And Weight Loss</brief_title>
  <official_title>A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XBiotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XBiotech, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the True Human Monoclonal antibody MABp1 can
      prolong the life of colorectal carcinoma patients who are losing weight.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>baseline to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference in median overall survival will be compared between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Tissue</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">656</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Cachexia</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>MABp1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MABp1 administered IV every two weeks, plus best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>megestrol acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>megestrol acetate administered daily plus best supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MABp1</intervention_name>
    <description>MABp1 is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks for as long as the patient is benefiting clinically.</description>
    <arm_group_label>MABp1</arm_group_label>
    <other_name>Xilonix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>megestrol acetate oral suspension will be administered daily for as long as the patient is benefiting clinically.</description>
    <arm_group_label>megestrol acetate</arm_group_label>
    <other_name>Megace</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or
             unresectable and which is refractory to standard therapy.  To be considered
             refractory, a subject must have failed both an oxaliplatin and an irinotecan based
             regimen.

          2. Weight loss of â‰¥5% over the last 6 months.

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2.

          4. Palliative radiation and/or chemotherapy are permitted after the initial 2 week
             washout period.

        Exclusion Criteria:

          1. Mechanical obstruction that would prevent adequate oral nutritional intake.

          2. Serious uncontrolled medical disorder, or active infection, that would impair the
             ability of the patient to receive protocol therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Stecher, M.D.</last_name>
    <phone>512-386-2900</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christopher DiSimone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Torres</last_name>
      <phone>714-446-5642</phone>
      <email>MarieGail.Torres@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>David Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Heavey</last_name>
      <phone>858-534-5532</phone>
      <email>sheavey@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Roeland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angelos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loni Lee</last_name>
      <phone>310-967-4335</phone>
      <email>Loni.Lee@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center and LAC USC Medical Center</name>
      <address>
        <city>Los Angelos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Agafitei</last_name>
      <phone>323-865-0467</phone>
      <email>Raluca.Agafitei@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Afsaneh Barzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flordeliza Mendoza</last_name>
      <phone>650-724-2056</phone>
      <email>flormend@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>George Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Christopher Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora, Denver, Boulder, Colorado Springs, Lakewood, Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Allen Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialists</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Ucar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lewis Hall Singletary Oncology Center</name>
      <address>
        <city>Thomasville</city>
        <state>Georgia</state>
        <zip>31792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Hilliard, MS,CCRC</last_name>
      <phone>229-584-5468</phone>
      <email>chilliard@archbold.org</email>
    </contact>
    <investigator>
      <last_name>Teresa Coleman, MD,FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Zack</last_name>
      <phone>313-576-9385</phone>
      <email>zackc@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Minsig Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aminah Jatoi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Ritcher</last_name>
      <email>glritcher@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Fa-Chyi Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srikanth Gajavelli</last_name>
      <phone>718-920-6193</phone>
      <email>sgajavel@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Ghalib</last_name>
      <phone>(718) 405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Given</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27110</phone_ext>
      <email>NGiven@ohcare.com</email>
    </contact>
    <investigator>
      <last_name>Irfan Firdaus, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialist, P.C</name>
      <address>
        <city>Portland and Yualatin</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Spencer Shao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann R Ackler</last_name>
      <phone>215-456-8295</phone>
      <email>acklerj@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>John Leighton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Tucker</last_name>
      <phone>423-698-1844</phone>
      <email>ktucker@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Mark Womack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Medical Center Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randi R Ray, RN,BSN,OCN</last_name>
      <phone>865-305-9773</phone>
      <email>RRRay@mc.utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Wahid Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PPLC SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Calvert</last_name>
      <phone>615-329-7235</phone>
      <email>Sharon.Calvert@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Johannna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Bedford and Grapevine</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristi McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Consultants, P.A.</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Rutt</last_name>
      <phone>817-759-7022</phone>
      <email>RRutt@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Henry Xiong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Forth Worth</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Asad Dean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview and Tyler</name>
      <address>
        <city>Longview and Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of South Texas-HOAST</name>
      <address>
        <city>New Braunfels and San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.pope@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Zweibach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Smith</last_name>
      <phone>210-916-3332</phone>
      <email>peggy.s.smith56.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Alexander Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dedra Preece</last_name>
      <phone>254-724-5939</phone>
      <email>DPREECE@sw.org</email>
    </contact>
    <investigator>
      <last_name>Lucas Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of TX Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benji Hawkins</last_name>
      <phone>903-877-5831</phone>
      <email>benji.hawkins@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Hitesh Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Newport News, Hampton, Norfolk, Virginia Beach, and Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pope</last_name>
      <phone>281-863-6544</phone>
      <email>Melissa.Pope@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>David Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialist, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pivotal</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Survival</keyword>
  <keyword>Phase 3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
